Gilead gets neutral rating from Merrill

Merrill Lynch analyst Eric Ende rated Gilead Sciences Inc. at neutral after the company announced a $2.5 billion cash offer for Myogen. The analyst sees the deal as a near-term negative but long-term positive given the drug ambrisentan. Merrill projects U.S. ambrisentan sales of $750 million by 2012. Shares of the Foster City, Calif.-based biopharmaceutical company were down $4.49, or 6.53%, at $64.28. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.